Gary H. Lyman, MD, MPH, FASCO, FRCP (Edin)
Co-Director, Hutchinson Institute for Cancer Outcomes Research (HICOR)
Public Health Sciences and Clinical Research Divisions
Fred Hutchinson Cancer Research Center
Professor of Medicine/Medical Oncology, University of Washington School of Medicine
Seattle Cancer Care Alliance
825 Eastlake Ave East
Seattle, WA 98109-1023
Specialty / Expertise
- Practicing medical oncologist
- Member, Public Health Sciences Division, Fred Hutchinson Cancer Research Center
- Member, Clinical Research Division, Fred Hutchinson Cancer Research Center
- Comparative Effectiveness Research of Novel Diagnostic and Therapeutic Strategies
- Clinical Decision Making, Risk Modeling, and Precision Medicine
- Health Technology Assessment and Research Synthesis
- Health Disparities and Quality of Cancer Care Delivery
- Health Economics, Pharmacoeconomics and Healthcare Policy
- Cancer Treatment and Supportive Care in the Elderly
Current Research Projects
- Personalized cancer supportive care through risk stratification and targeted intervention; Systematic evidence summaries of several clinical practice topics in support of ASCO clinical practice guidelines;
- Defining and measuring the value of cancer care using multi-stakeholder engagement (HICOR)
Dr Lyman received his BA and MD through the State University of New York at Buffalo and an MPH in Biostatistics at the Harvard School of Public Health. He completed his Internal Medicine Residency at the University of North Carolina in Chapel Hill and his Fellowships in Hematology and Medical Oncology at the Roswell Park Memorial Institute as well as a postdoctoral fellowship at the Dana Farber Cancer Center in Boston.
Peppercorn J, Houck K, Beri N, Villagra V, Wogu AF, Lyman GH, Wheeler SB. Breast cancer screening utilization and understanding of current guidelines among rural U.S. women with private insurance. Breast Cancer Res Treat. 2015 Sep 19. [Epub ahead of print]
Dinan MA, Mi X, Reed SD, Lyman GH, Curtis LH. Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009. JAMA Oncol. 2015 Aug 27. doi: 10.1001/jamaoncol.2015.2722. [Epub ahead of print]
Schnipper LE, Davidson NE, Wollins DS, Tyne C, Blayney DW, Blum D, Dicker AP, Ganz PA, Hoverman JR, Langdon R, Lyman GH, Meropol NJ, Mulvey T, Newcomer L, Peppercorn J, Polite B, Raghavan D, Rossi G, Saltz L, Schrag D, Smith TJ, Yu PP, Hudis CA, Schilsky RL. American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. J Clin Oncol. 2015 Aug 10;33(23):2563-77. doi: 10.1200/JCO.2015.61.6706. Epub 2015 Jun 22.
Lyman GH, Dale DC, Legg JC, Abella E, Morrow PK, Whittaker S, Crawford J. Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk? Cancer Med. 2015 Aug;4(8):1153-60. doi: 10.1002/cam4.454. Epub 2015 Mar 23.
Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015 Jul 13. pii: JCO.2015.62.3488. [Epub ahead of print]
Lyman GH, Crawford J, Tomita D, Whittaker S, Dale DC. Changing patterns of chemotherapy relative dose intensity and supportive care for aggressive B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2015 Jul 7:1-8. [Epub ahead of print]
Schwartzberg L, Harrow B, Lal LS, Radtchenko J, Lyman GH. Resource Utilization for Chemotherapy-Induced Nausea and Vomiting Events in Patients with Solid Tumors Treated with Antiemetic Regimens. Am Health Drug Benefits. 2015 Jul-Aug;8(5):273-82.
Ramsey SD, Fedorenko C, Chauhan R, McGee R, Lyman GH, Kreizenbeck K, Bansal A. Baseline Estimates of Adherence to American Society of Clinical Oncology/American Board of Internal Medicine Choosing Wisely Initiative Among Patients With Cancer Enrolled With a Large Regional Commercial Health Insurer. J Oncol Pract. 2015 Jul;11(4):338-43. doi: 10.1200/JOP.2014.002717. Epub 2015 Jun 9.
Lyman GH, Reiner M, Morrow PK, Crawford J. The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy. Ann Oncol. 2015 Jul;26(7):1452-8. doi: 10.1093/annonc/mdv174. Epub 2015 Apr 7.
11: Lyman GH, Kuderer NM. When to Offer Thromboprophylaxis to Patients With Advanced Pancreatic Cancer: Shedding Light on the Path Forward. J Clin Oncol. 2015 Jun 20;33(18):1995-7. doi: 10.1200/JCO.2015.61.4164. Epub 2015 May 18.
Dinan MA, Mi X, Reed SD, Hirsch BR, Lyman GH, Curtis LH. Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009. JAMA Oncol. 2015 May 1;1(2):158-66. doi: 10.1001/jamaoncol.2015.43.
Lyman GH, Bohlke K, Falanga A. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Oncol Pract. 2015 May;11(3):e442-4.
Browman GP, Somerfield MR, Lyman GH, Brouwers MC. When is good, good enough? Methodological pragmatism for sustainable guideline development. Implement Sci. 2015 Mar 6;10:28.
Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Somerfield MR, Falanga A; American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. J Clin Oncol. 2015 Feb 20;33(6):654-6. doi: 10.1200/JCO.2014.59.7351. Epub 2015 Jan 20.
Lyman GH. Appropriate role for sentinel node biopsy after neoadjuvant chemotherapy in patients with early-stage breast cancer. J Clin Oncol. 2015 Jan 20;33(3):232-4. doi: 10.1200/JCO.2014.58.9838. Epub 2014 Dec 8.
Culakova E, Poniewierski MS, Wolff DA, Dale DC, Crawford J, Lyman GH. The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort study. Springerplus. 2015 Aug 6;4:396.
Dinan MA, Hirsch BR, Lyman GH. Management of chemotherapy-induced neutropenia: measuring quality, cost, and value. J Natl Compr Canc Netw. 2015 Jan;13(1):e1-7. Review.
Schully SD, Lam TK, Dotson WD, Chang CQ, Aronson N, Birkeland ML, Brewster SJ, Boccia S, Buchanan AH, Calonge N, Calzone K, Djulbegovic B, Goddard KA, Klein RD, Klein TE, Lau J, Long R, Lyman GH, Morgan RL, Palmer CG, Relling MV, Rubinstein WS, Swen JJ, Terry SF, Williams MS, Khoury MJ. Evidence synthesis and guideline development in genomic medicine: current status and future prospects. Genet Med. 2015 Jan;17(1):63-7. doi: 10.1038/gim.2014.69. Epub 2014 Jun 19.
Weycker D, Li X, Edelsberg J, Barron R, Kartashov A, Xu H, Lyman GH. Risk and Consequences of Chemotherapy-Induced Febrile Neutropenia in Patients With Metastatic Solid Tumors. J Oncol Pract. 2014 Dec 9. pii: JOP.2014.001492. [Epub ahead of print]
Weycker D, Li X, Edelsberg J, Barron R, Kartashov A, Xu H, Lyman GH. Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens. Support Care Cancer. 2014 Dec;22(12):3275-85.
Last updated: October 2015